Actionnariat et activité des initiés pour Coherus Oncology, Inc. (CHRS): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $1.22 |
| Capitalisation | $188M |
| Bourse | NASDAQ |
| Pays | US |
Transactions d'Initiés Récentes
| Date | Initié | Type | Actions | Valeur |
|---|---|---|---|---|
| 2026-06-05 | Satvat Ali J. | A-Award | 60,000 | $87K |
| 2026-06-05 | Satvat Ali J. | A-Award | 30,000 | |
| 2026-06-05 | Karachun Rita A | A-Award | 60,000 | $87K |
| 2026-06-05 | Karachun Rita A | A-Award | 30,000 | |
| 2026-06-05 | Newcomer Lee Nisley | A-Award | 60,000 | $87K |
| 2026-06-05 | Newcomer Lee Nisley | A-Award | 30,000 | |
| 2026-06-05 | Ryan Michael Lee | A-Award | 60,000 | $87K |
| 2026-06-05 | Ryan Michael Lee | A-Award | 30,000 | |
| 2026-06-05 | O'Donnell-Tormey Jill | A-Award | 60,000 | $87K |
| 2026-06-05 | O'Donnell-Tormey Jill | A-Award | 30,000 |
Bilan (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $124.9M | $126.9M | $72.4M | $177.7M | $541.2M | $417.2M | $63.5M | $102.9M | $126.0M | $88.9M |
| Placements à Court Terme | 0 | 0 | 0 | 0 | 0 | 0 | $128.1M | $14.9M | 0 | $83.2M |
| Créances | $1.9M | 0 | 0 | $142.0M | $157.0M | $123.0M | $110.0M | $260.5M | $122.3M | $18.4M |
| Stocks | -$4.8M | 0 | $1.7M | $9.8M | $44.2M | $37.6M | $38.8M | $62.6M | $70.1M | $3.2M |
| Actifs Courants | $124.9M | $126.9M | $72.4M | $343.0M | $767.5M | $602.3M | $381.2M | $475.6M | $341.6M | $206.7M |
| Immobilisations Corporelles | $10.8M | $12.8M | $6.7M | $16.5M | $10.1M | $7.8M | $8.8M | $5.1M | $2.8M | $1.3M |
| Goodwill | $943000 | $943000 | $943000 | $943000 | $943000 | $943000 | $943000 | $943000 | 0 | 0 |
| Actifs Incorporels | $2.6M | $2.6M | $2.6M | $2.6M | $2.6M | $2.6M | $5.0M | $70.7M | $53.6M | $46.2M |
| Actifs Totaux | $178.5M | $162.6M | $99.5M | $408.9M | $841.6M | $679.3M | $480.8M | $629.6M | $448.5M | $258.3M |
| Dettes Fournisseurs | $20.6M | $15.7M | $15.3M | $26.0M | $15.2M | $16.2M | $11.5M | $35.2M | $28.5M | $9.9M |
| Dette à Court Terme | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Passifs Courants | $56.4M | $28.4M | $33.3M | $115.0M | $145.7M | $165.3M | $138.7M | $331.8M | $283.0M | $141.9M |
| Dette à Long Terme | $100.3M | $101.6M | $103.1M | $178.4M | $404.0M | $408.3M | $471.1M | $473.4M | $264.9M | $37.1M |
| Passifs Totaux | $159.1M | $132.1M | $138.1M | $303.7M | $560.7M | $581.6M | $618.3M | $823.0M | $580.5M | $197.3M |
| Réserves | -$537.3M | -$775.5M | -$984.8M | -$895.0M | -$762.8M | -$1.05B | -$1.34B | -$1.58B | -$1.55B | -$1.38B |
| Capitaux Propres | $19.4M | $30.5M | -$38.6M | $105.2M | $281.0M | $97.7M | -$137.4M | -$193.4M | -$132.0M | $61.0M |
| Dette Totale | $100.3M | $101.4M | $103.1M | $188.6M | $417.1M | $419.0M | $480.4M | $480.8M | $269.9M | $40.3M |
| Dette Nette | -$24.7M | -$25.5M | $30.7M | $11.0M | -$124.1M | $1.8M | $288.7M | $363.1M | $143.9M | -$131.8M |
| Fonds de Roulement | $68.6M | $98.5M | $39.1M | $228.0M | $621.8M | $437.0M | $242.5M | $143.9M | $58.6M | $64.8M |
Santé financière
| Dette / Capitaux propres | 0.62 |
| Ratio de liquidité | 1.77 |
Rentabilité
| Rentabilité des capitaux propres | -181.73% |
| Rentabilité du capital investi | -135.38% |
| Rentabilité des actifs | -68.50% |
| Marge brute | 63.55% |
| Marge opérationnelle | -307.43% |
| Marge nette | -257.10% |
Entreprises liées: AVTX · CCCC · CDXS · IMDX · IVVD · OABI · PLX
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de CHRS: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions